Victory Capital Management Inc Tricida, Inc. Transaction History

Victory Capital Management Inc

8 transactions

Quarter	Operation	Price Per share	shares change	shares Held
Q3 2022 Nov 02, 2022	SELL	$8.51 - $13.6 $1.44 Million - $2.31 Million	-169,665 Reduced 87.48%	24,284 $254,000
Q2 2022 Aug 01, 2022	BUY	$7.31 - $11.85 $533,476 - $864,801	72,979 Added 60.33%	193,949 $1.88 Million
Q1 2022 May 04, 2022	BUY	$7.35 - $10.63 $889,129 - $1.29 Million	120,970 New	120,970 $994,000
Q2 2020 Aug 07, 2020	SELL	$21.21 - $31.55 $131,883 - $196,177	-6,218 Closed	0 $0
Q1 2020 May 04, 2020	SELL	$18.43 - $38.04 $24,235 - $50,022	-1,315 Reduced 17.46%	6,218 $137,000
Q4 2019 Feb 06, 2020	BUY	$29.6 - $43.71 $33,033 - $48,780	1,116 Added 17.39%	7,533 $284,000
Q4 2019 Feb 04, 2020	SELL	$29.6 - $43.71 $19,595 - $28,936	-662 Reduced 9.35%	6,417 $226,000
Q3 2019 Nov 12, 2019	BUY	$29.87 - $42.22 $211,449 - $298,875	7,079 New	7,079 $219,000

30K

124K

46.5K

Ticker TCDA
Exchange NASDAQ
Sector Healthcare
Industry Biotechnology
Shares Outstandng 55,668,900
Market Cap $557K
Description
Tricida, Inc. operates as a pharmaceutical company. It focuses on the development and commercialization of veverimer (TRC101), a non-absorbed orally-administered polymer that has completed Phase III trial to treat metabolic acidosis in patients with chronic kidney disease by binding and removing acid from the gastrointestinal track. The company ...

Get notified when there are updates to the investment portfolio of Victory Capital Management Inc, based on Form 13F filings with the SEC.

Stay updated on Victory Capital Management Inc with notifications on news.